SPC1001 Low
Phase 2Small molecule
SPC1001 Low is one of 29 small molecule programs targeting Essential Hypertension. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
238 competitors in Essential Hypertension
#DrugCompanyPhaseTrials
1Edarbi
TakedaPhase 3
Benicar
NovartisPhase 3
Edarbi
TakedaPhase 3
Crestor
AstraZenecaPhase 3
Thalitone
Alnylam PharmaceuticalsPhase 3
Atacand
IIstituto Clinico Humanitas
Phase 3
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Zocor
OOrganon and Co
Phase 3
Aceon
Institut de Recherches Internationales ServierPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SPC1001 Low. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details